Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT
Mao, Jie, Yang, Hongbao, Cui, Tingting, Pan, Pan, Kabir, Nadia, Chen, Duo, Ma, Jinyan, Chen, Xingyi, Chen, Yijun, Yang, YongТом:
832
Мова:
english
Журнал:
European Journal of Pharmacology
DOI:
10.1016/j.ejphar.2018.05.027
Date:
August, 2018
Файл:
PDF, 2.25 MB
english, 2018
File converter
Більше результатів пошуку
More benefits 
